Phil Green PhD Chesapeake Pharma

Phil Green is currently President of Chesapeake Pharma LLC, a drug delivery consulting company. Phil has extensive experience in the pharmaceutical industry in the development and commercialization of novel drug delivery products. Phil has a specific focus on commercial aspects of combination drug-devices, IV to subcutaneous switching of biopharmaceutical products and an in depth knowledge of the pipeline of injectable drugs. From 2009 to 2018, Phil was Executive Director, Biologics Device Strategy at Merck US. In this role he was responsible for devising commercial device strategies around subcutaneous device-based combination products for multiple biosimilar and novel immuno-oncology agents. Prior to Merck, Phil worked for 16 years with Becton-Dickinson where he was responsible for creating business partnerships with Pharma Co’s for Advanced Delivery Technology including transdermal, intradermal, microneedle and high volume subcutaneous injection devices. Before joining Becton-Dickinson he held multiple drug delivery development roles with Novartis (Zyma), Switzerland and L’Oreal/Galderma, France. Phil received his BSc in Chemistry and MSc in Medical Sciences from Bristol University, UK, a PhD in Pharmaceutical Chemistry from The School of Pharmacy Dept, Cardiff University, Wales UK and post doctoral research in protein and peptide transdermal delivery at University of California, San Francisco.